Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
CHICAGO - Savara Inc. (NASDAQ:SVRA), a $737 million market cap biotechnology company with strong financial health metrics according to InvestingPro, announced that its partner TrilliumBiO will present data on the development of a dried serum assay for detecting GM-CSF antibodies to aid in diagnosing autoimmune pulmonary alveolar proteinosis (aPAP) at the upcoming CHEST 2025 conference.
The presentation, scheduled for October 22 in Chicago, will be among three Savara-related abstracts accepted for the medical conference. According to the press release, TrilliumBiO’s poster will focus on a potential diagnostic tool for aPAP, a rare lung disease characterized by abnormal surfactant buildup in the lungs.
Savara will also present data on its investigational treatment molgramostim, including an oral presentation on the drug’s efficacy according to aPAP severity and a poster examining relationships between pulmonary gas transfer, quality of life, exercise capacity, and surfactant burden in aPAP patients. With analyst price targets ranging from $7 to $16, the market shows significant interest in the company’s development pipeline.
Additionally, the company will host a learning theater titled "Advances in Autoimmune Pulmonary Alveolar Proteinosis" on October 21, featuring Kevin Davidson, M.D., who will discuss the disease’s pathophysiology, symptoms, diagnosis, and management.
Savara’s lead program, molgramostim inhalation solution, is a recombinant human GM-CSF currently in Phase 3 development for aPAP. The treatment is delivered via a proprietary investigational eFlow Nebulizer System.
The CHEST 2025 conference will take place from October 19-22 at McCormick Place in Chicago. For investors seeking deeper insights into Savara’s financial health and growth potential, InvestingPro offers comprehensive analysis through its Pro Research Report, including detailed metrics showing the company maintains more cash than debt and a strong current ratio of 11.08.
In other recent news, Savara Inc. announced positive results from its Phase 3 IMPALA-2 trial of molgramostim in treating autoimmune pulmonary alveolar proteinosis (aPAP). The trial demonstrated that the inhaled therapy improved lung diffusing capacity compared to placebo, benefiting patients regardless of disease severity. Additionally, Savara shared that it has aligned with the FDA on Biologics License Application resubmission requirements for its drug Molbreevi, which contributed to Guggenheim raising its price target on the company’s stock to $11. H.C. Wainwright also increased its price target to $8, following an analysis of a larger patient pool for aPAP in the United States. JMP Securities reiterated its Market Outperform rating and maintained an $8 price target, citing the robust findings from the IMPALA-2 trial published in the New England Journal of Medicine. This publication highlighted the significant improvements in pulmonary gas transfer for patients treated with Molbreevi. These developments reflect ongoing advancements and interest in Savara’s treatment for aPAP.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.